01 1Cambrex Corporation
01 1FENTANYL CITRATE USP
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-12
Pay. Date : 2013-01-23
DMF Number : 17055
Submission : 2003-12-19
Status : Active
Type : II
20
Cambrex Charles City Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Cambrex is an innovative life sciences company with a refreshingly human approach.
One of their notable products is FENTANYL CITRATE USP, with a corresponding US DMF Number 17055.
Remarkably, this DMF maintains an Active status since its submission on December 19, 2003, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 12, 2013, and payment made on January 23, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II
